drugset / Trial / NCT04884256

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula

NCT04884256 ↗

Phase 2 Completed 88 enrolled Cloudbreak Therapeutics, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications. Dosage/Dose regimen: One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the more severe vascularity grade at Visit 1 will be the study eye.

Timeline

Start
2023-12-21
Primary completion
2025-04-17
Completion
2025-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CBT-004 Unknown 0.05 % Topical
Subject CBT-004 Unknown 0.075 % Topical

Indications